Event Date/Time: Sep 26, 2005
End Date/Time: Sep 28, 2005
In an attempt to avoid expensive late-stage candidate failures, pharmaceutical companies apply increasingly stringent compound characterization and selection processes. Gene expression profiling is becoming increasingly adopted in small molecule drug development programs to characterize pharmacological and toxicological activity. The meeting addresses the role of expression profiling in providing better understanding of compound’s mechanism of action and target selectivity, impact on toxicity pathways and other potential liabilities, and making candidate selection decisions early in the drug discovery process.